OVA-E1 peptide

OVA-E1 peptide, is an antagonist variant of SIINFEKL [OVA (257-264) . OVA-E1 peptide, activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes[1].

Product Specifications

CAS Number

[153316-01-9]

UNSPSC

12352209

Hazard Statement

H315-H319-H335

Target

JNK; p38 MAPK

Type

Peptides

Related Pathways

MAPK/ERK Pathway

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ova-e1-peptide.html

Solubility

H2O

Smiles

O=C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(N)=O)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCC(O)=O)N

Molecular Formula

C47H76N10O14

Molecular Weight

1005.16

Precautions

P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P362+P364-P403+P233-P405-P501

References & Citations

[1]Leandro J Carreño, et al. The Half-Life of the T-cell receptor/peptide-major Histocompatibility Complex Interaction Can Modulate T-cell Activation in Response to Bacterial Challenge. Immunology. 2007 Jun;121 (2) :227-37.